Stem cell transplantation in patients with severe congenital neutropenia with evidence of leukemic transformation

S. W. Choi, L. A. Boxer, M. A. Pulsipher, D. Roulston, R. J. Hutchinson, G. A. Yanik, Kenneth R Cooke, J. L M Ferrara, J. E. Levine

Research output: Contribution to journalArticle

Abstract

Severe congenital neutropenia (SCN) is a hematologic condition characterized by arrested maturation of myelopoiesis at the promyelocyte stage of development. With appropriate treatment using recombinant human granulocyte-colony-stimulating factor (r-HuG-CSF), SCN patients are now surviving longer, but are at increased risk of developing myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML). Hematopoietic stem cell transplantation (HSCT) is the only curative option for these patients, but transplantation outcomes after malignant transformation are not well established. We report results for six patients with SCN who underwent HSCT for MDS or AML between 1997 and 2001 at two transplant centers. Two patients transplanted for MDS survived. Both of these patients were transplanted without being given induction chemotherapy. Four patients, who all received induction chemotherapy for AML prior to HSCT, died. Administering induction chemotherapy prior to HSCT resulted in significant morbidity. Rapid transplantation should be the goal for the SCN patient once the diagnosis of MDS/AML is established. SCN patients should be monitored carefully for progression to MDS in order to be treated with HSCT as soon as they have progressed and before developing AML. For SCN patients who progress to AML, HSCT should still be considered, even though the risks appear to be greater.

Original languageEnglish (US)
Pages (from-to)473-477
Number of pages5
JournalBone Marrow Transplantation
Volume35
Issue number5
DOIs
StatePublished - Mar 2005
Externally publishedYes

Fingerprint

Stem Cell Transplantation
Hematopoietic Stem Cell Transplantation
Acute Myeloid Leukemia
Myelodysplastic Syndromes
Induction Chemotherapy
Transplantation
Myelopoiesis
Neutropenia, Severe Congenital, Autosomal Recessive 3
Granulocyte Precursor Cells
Granulocyte Colony-Stimulating Factor
Morbidity
Transplants

Keywords

  • Acute myelogenous leukemia
  • Hematopoietic stem cell transplantation
  • Myelodysplastic syndrome
  • Neutropenia
  • Recombinant-methionyl human granulocyte-colony-stimulating factor

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Choi, S. W., Boxer, L. A., Pulsipher, M. A., Roulston, D., Hutchinson, R. J., Yanik, G. A., ... Levine, J. E. (2005). Stem cell transplantation in patients with severe congenital neutropenia with evidence of leukemic transformation. Bone Marrow Transplantation, 35(5), 473-477. https://doi.org/10.1038/sj.bmt.1704813

Stem cell transplantation in patients with severe congenital neutropenia with evidence of leukemic transformation. / Choi, S. W.; Boxer, L. A.; Pulsipher, M. A.; Roulston, D.; Hutchinson, R. J.; Yanik, G. A.; Cooke, Kenneth R; Ferrara, J. L M; Levine, J. E.

In: Bone Marrow Transplantation, Vol. 35, No. 5, 03.2005, p. 473-477.

Research output: Contribution to journalArticle

Choi, SW, Boxer, LA, Pulsipher, MA, Roulston, D, Hutchinson, RJ, Yanik, GA, Cooke, KR, Ferrara, JLM & Levine, JE 2005, 'Stem cell transplantation in patients with severe congenital neutropenia with evidence of leukemic transformation', Bone Marrow Transplantation, vol. 35, no. 5, pp. 473-477. https://doi.org/10.1038/sj.bmt.1704813
Choi, S. W. ; Boxer, L. A. ; Pulsipher, M. A. ; Roulston, D. ; Hutchinson, R. J. ; Yanik, G. A. ; Cooke, Kenneth R ; Ferrara, J. L M ; Levine, J. E. / Stem cell transplantation in patients with severe congenital neutropenia with evidence of leukemic transformation. In: Bone Marrow Transplantation. 2005 ; Vol. 35, No. 5. pp. 473-477.
@article{ddf4b410d9a544288b5074b7682a9641,
title = "Stem cell transplantation in patients with severe congenital neutropenia with evidence of leukemic transformation",
abstract = "Severe congenital neutropenia (SCN) is a hematologic condition characterized by arrested maturation of myelopoiesis at the promyelocyte stage of development. With appropriate treatment using recombinant human granulocyte-colony-stimulating factor (r-HuG-CSF), SCN patients are now surviving longer, but are at increased risk of developing myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML). Hematopoietic stem cell transplantation (HSCT) is the only curative option for these patients, but transplantation outcomes after malignant transformation are not well established. We report results for six patients with SCN who underwent HSCT for MDS or AML between 1997 and 2001 at two transplant centers. Two patients transplanted for MDS survived. Both of these patients were transplanted without being given induction chemotherapy. Four patients, who all received induction chemotherapy for AML prior to HSCT, died. Administering induction chemotherapy prior to HSCT resulted in significant morbidity. Rapid transplantation should be the goal for the SCN patient once the diagnosis of MDS/AML is established. SCN patients should be monitored carefully for progression to MDS in order to be treated with HSCT as soon as they have progressed and before developing AML. For SCN patients who progress to AML, HSCT should still be considered, even though the risks appear to be greater.",
keywords = "Acute myelogenous leukemia, Hematopoietic stem cell transplantation, Myelodysplastic syndrome, Neutropenia, Recombinant-methionyl human granulocyte-colony-stimulating factor",
author = "Choi, {S. W.} and Boxer, {L. A.} and Pulsipher, {M. A.} and D. Roulston and Hutchinson, {R. J.} and Yanik, {G. A.} and Cooke, {Kenneth R} and Ferrara, {J. L M} and Levine, {J. E.}",
year = "2005",
month = "3",
doi = "10.1038/sj.bmt.1704813",
language = "English (US)",
volume = "35",
pages = "473--477",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Stem cell transplantation in patients with severe congenital neutropenia with evidence of leukemic transformation

AU - Choi, S. W.

AU - Boxer, L. A.

AU - Pulsipher, M. A.

AU - Roulston, D.

AU - Hutchinson, R. J.

AU - Yanik, G. A.

AU - Cooke, Kenneth R

AU - Ferrara, J. L M

AU - Levine, J. E.

PY - 2005/3

Y1 - 2005/3

N2 - Severe congenital neutropenia (SCN) is a hematologic condition characterized by arrested maturation of myelopoiesis at the promyelocyte stage of development. With appropriate treatment using recombinant human granulocyte-colony-stimulating factor (r-HuG-CSF), SCN patients are now surviving longer, but are at increased risk of developing myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML). Hematopoietic stem cell transplantation (HSCT) is the only curative option for these patients, but transplantation outcomes after malignant transformation are not well established. We report results for six patients with SCN who underwent HSCT for MDS or AML between 1997 and 2001 at two transplant centers. Two patients transplanted for MDS survived. Both of these patients were transplanted without being given induction chemotherapy. Four patients, who all received induction chemotherapy for AML prior to HSCT, died. Administering induction chemotherapy prior to HSCT resulted in significant morbidity. Rapid transplantation should be the goal for the SCN patient once the diagnosis of MDS/AML is established. SCN patients should be monitored carefully for progression to MDS in order to be treated with HSCT as soon as they have progressed and before developing AML. For SCN patients who progress to AML, HSCT should still be considered, even though the risks appear to be greater.

AB - Severe congenital neutropenia (SCN) is a hematologic condition characterized by arrested maturation of myelopoiesis at the promyelocyte stage of development. With appropriate treatment using recombinant human granulocyte-colony-stimulating factor (r-HuG-CSF), SCN patients are now surviving longer, but are at increased risk of developing myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML). Hematopoietic stem cell transplantation (HSCT) is the only curative option for these patients, but transplantation outcomes after malignant transformation are not well established. We report results for six patients with SCN who underwent HSCT for MDS or AML between 1997 and 2001 at two transplant centers. Two patients transplanted for MDS survived. Both of these patients were transplanted without being given induction chemotherapy. Four patients, who all received induction chemotherapy for AML prior to HSCT, died. Administering induction chemotherapy prior to HSCT resulted in significant morbidity. Rapid transplantation should be the goal for the SCN patient once the diagnosis of MDS/AML is established. SCN patients should be monitored carefully for progression to MDS in order to be treated with HSCT as soon as they have progressed and before developing AML. For SCN patients who progress to AML, HSCT should still be considered, even though the risks appear to be greater.

KW - Acute myelogenous leukemia

KW - Hematopoietic stem cell transplantation

KW - Myelodysplastic syndrome

KW - Neutropenia

KW - Recombinant-methionyl human granulocyte-colony-stimulating factor

UR - http://www.scopus.com/inward/record.url?scp=15544363068&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15544363068&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1704813

DO - 10.1038/sj.bmt.1704813

M3 - Article

C2 - 15640815

AN - SCOPUS:15544363068

VL - 35

SP - 473

EP - 477

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 5

ER -